Treatment Gaps in Paediatric ADHD Pharmacotherapy: A 10-Year Nationwide Cohort Study from Hungary
This 10-year nationwide cohort study in Hungary reveals significant gaps in paediatric ADHD pharmacotherapy, characterized by low treatment initiation rates, marked regional disparities, a counter-guideline preference for atomoxetine over methylphenidate despite higher persistence with the latter, and frequent off-label antipsychotic use.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the human brain as a bustling city. In this city, some people have a traffic control system that works a little differently; their cars (thoughts) zoom around too fast, or they get stuck in gridlock, making it hard to get to school, keep friends, or finish homework. This is what doctors call Attention-Deficit/Hyperactivity Disorder, or ADHD. To help these drivers, scientists have developed special "traffic lights" in the form of medicine. Some lights are bright and fast-acting (stimulants), while others are steady and slow-burning (non-stimulants). The big question for doctors everywhere is: Are we actually handing out these traffic lights to the drivers who need them? And if we do, are the drivers sticking with the plan, or are they tossing the lights out the window? This is the story of a massive detective hunt across Hungary, where researchers looked at ten years of medical records to see if the city's traffic rules were being followed or if the roads were left in chaos.
This paper is a ten-year nationwide investigation into how children with ADHD in Hungary are treated with medicine. The researchers acted like detectives, sifting through the health insurance records of 36,091 children who were newly diagnosed with ADHD between 2013 and 2022. They wanted to answer three big questions: How many kids actually get medicine? Which kind of medicine do doctors pick first? And do the kids keep taking it, or do they stop?
The first thing the detectives found was a massive "missing person" case. Even though the healthcare system is centralized and supposed to be fair, only about one in five (21.7%) of the diagnosed children actually started taking ADHD-specific medicine. It's as if a city planner diagnosed a traffic jam but only gave out traffic lights to 20% of the drivers. The situation was even worse in some neighborhoods than others; in one region, only 11.8% of kids got help, while in another, nearly 30% did. This 2.5-fold difference suggests that where a child lives changes their chances of getting help more than anything else.
When the researchers looked at who got the medicine, they found a clear gender gap. Boys were much more likely to get a prescription (23.3%) than girls (15.8%). It seems the "traffic lights" are being handed out mostly to the drivers who are causing the loudest noise, while the quieter drivers (often girls) are left waiting in the dark. Age also played a role: the most likely group to get medicine was the 11-to-14-year-olds, while the youngest kids (0–6) and the oldest teens (15–18) were often left untreated.
Perhaps the most surprising twist in the story was which medicine was chosen. Medical guidelines usually suggest starting with the fast-acting "traffic lights" (methylphenidate) because they are the most effective. However, in Hungary, doctors overwhelmingly chose the slow-burning option (atomoxetine) first. About two-thirds (65.0%) of the treated children started on atomoxetine, while only 35% started on methylphenidate. The researchers suspect this happened because the fast-acting medicine is harder to prescribe (it requires more paperwork) and costs families more money, while the slow-burning one is cheaper for them.
The story didn't end with just handing out the medicine; the researchers also checked if the kids kept using it. They found that sticking to the plan was a struggle for everyone, but it was a bigger struggle for the fast-acting medicine. After six months, only about half (50.9%) of the kids taking methylphenidate were still on it, compared to nearly two-thirds (63.4%) of those taking atomoxetine. It's like the fast-acting lights were so intense that many drivers turned them off after a few months, while the steady lights were easier to keep running.
Finally, the detectives noticed something else happening on the roads: a significant number of children (9.4% of all diagnosed kids) were being given a different kind of drug entirely—antipsychotics. These are powerful medicines usually reserved for very different conditions, not typically for standard ADHD. The paper suggests that because ADHD-specific medicines are expensive or hard to get, some doctors might be reaching for these other drugs instead, even though the evidence doesn't strongly support this as a first choice.
In the end, this study reveals a city where the traffic rules are clear, but the execution is messy. Most diagnosed children aren't getting the right tools, the tools they do get are often the ones that are cheaper or easier to prescribe rather than the ones proven to work best, and many drivers are quitting the plan too soon. The authors conclude that to fix this, the country needs to change how medicines are paid for, train doctors to spot the quieter drivers (girls), and create a system where every child, no matter where they live, gets a fair shot at a clear road ahead.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.